A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/09/2006	CA2607089A1 Heterocyclic antiviral compounds
11/09/2006	CA2606815A1 Polymer conjugate enhanced bioassays
11/09/2006	CA2606804A1 Antimicrobial agents
11/09/2006	CA2606760A1 Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
11/09/2006	CA2606757A1 Substituted butyrophenone derivatives
11/09/2006	CA2606740A1 Quinine-containing controlled-release formulations
11/09/2006	CA2606716A1 Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
11/09/2006	CA2606688A1 Phospholipid formulations and uses thereof in lung disease detection and treatment
11/09/2006	CA2606683A1 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
11/09/2006	CA2606682A1 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
11/09/2006	CA2606679A1 Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-[4-((r)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
11/09/2006	CA2606650A1 Crystalline form of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
11/09/2006	CA2606599A1 Conjugated aromatic compounds for diagnosis and therapy
11/09/2006	CA2606552A1 Crystalline forms of tiotropium bromide
11/09/2006	CA2606550A1 Piperidine-substituted indoles
11/09/2006	CA2606549A1 Crystalline forms of tiotropium bromide
11/09/2006	CA2606538A1 3 -m0n0- and 3 , 5-disubstituted piperidine derivatives as renin inhibitors
11/09/2006	CA2606515A1 Method of improving learning and memory in mammals
11/09/2006	CA2606386A1 Therapeutic compositions
11/09/2006	CA2606382A1 Methods of supressing uv light-induced skin carcinogenesis
11/09/2006	CA2606341A1 Genemap of the human genes associated with crohn's disease
11/09/2006	CA2606338A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity
11/09/2006	CA2606315A1 Use of phycotoxins in veterinary applications
11/09/2006	CA2606269A1 Histamine h3-recept0r ligands and their therapeutic application
11/09/2006	CA2606262A1 Novel histamine h3-receptor ligands and their therapeutic applications
11/09/2006	CA2606188A1 Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
11/09/2006	CA2606177A1 Novel polypeptide and use thereof
11/09/2006	CA2606151A1 Composition for sleep inducer comprising essential oil as active ingredient, percutaneous sleep inducer comprising thereof, and method for producing thereof
11/09/2006	CA2606068A1 Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
11/09/2006	CA2605900A1 Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
11/09/2006	CA2605895A1 Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
11/09/2006	CA2605847A1 Ddp-iv inhibitors for the treatment of postprandial hyperlipidemia
11/09/2006	CA2605784A1 Antitumoral tetrahydro-pyrimidines
11/09/2006	CA2605773A1 Stable emulsion composition
11/09/2006	CA2605727A1 19,26,27-trinor-1.alpha.,25-dihydroxyvitamin d3 compounds
11/09/2006	CA2605473A1 Process for preparing quetiapine and quetiapine fumarate
11/09/2006	CA2605298A1 Crystal of hydroxynorephedrin derivative hydrochloride 1/4 hydrate
11/09/2006	CA2605295A1 6-11 bridged oxime erythromycin derivatives
11/09/2006	CA2605112A1 Solid transdermal therapeutic system comprising uv absorber
11/09/2006	CA2604617A1 Composition containing anti-dementia drug
11/09/2006	CA2604473A1 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
11/09/2006	CA2604424A1 Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
11/09/2006	CA2603060A1 Therapeutic agent for chronic obstructive pulmonary disease
11/09/2006	CA2602464A1 Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin d3 compounds
11/09/2006	CA2601067A1 Method of administering a cationic liposomal preparation comprising paclitaxel
11/09/2006	CA2600052A1 Benzotriazole derivatives as cannabinoid receptor antagonists
11/09/2006	CA2599411A1 Enzyme inhibitors
11/09/2006	CA2598491A1 Diastereoisomers of 4-hydroxyisoleucine and uses thereof
11/09/2006	CA2596023A1 Fatty acid-benzenediol derivatives and methods of making and using thereof
11/09/2006	CA2591586A1 Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
11/09/2006	CA2587485A1 8a, 9-dihydro-4a-h-isothiazolo[5,4-b] quinoline-3, 4-diones and related compounds as anti-infective agents
11/08/2006	EP1719779A2 Antibodies against Matin
11/08/2006	EP1719775A1 Camptothecins with a modified lactone ring
11/08/2006	EP1719774A2 Preventive or therapeutic agent for diabetic maculopathy
11/08/2006	EP1719773A1 Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
11/08/2006	EP1719771A1 Pyrazoloquinolone derivative and use thereof
11/08/2006	EP1719770A2 Quinoline derivatives as antibacterials
11/08/2006	EP1719768A1 Novel benzothiazepine and benzothiepine compounds
11/08/2006	EP1719767A1 Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
11/08/2006	EP1719765A1 Novel sulfone amide derivative
11/08/2006	EP1719763A1 Novel pyridine derivative and pyrimidine derivative (2)
11/08/2006	EP1719762A1 Novel pyridine derivative and pyrimidine derivative (1)
11/08/2006	EP1719761A1 Novel heterocyclic compound
11/08/2006	EP1719760A2 Fluvastatin sodium crystal form LXXXVII, processes for preparing it, compositions containing it and methods of using it
11/08/2006	EP1719759A2 Fluvastatin sodium crystal form LXXIII, processes for preparing it, compositions containing it and methods of using it
11/08/2006	EP1719757A1 Bicyclo derivative
11/08/2006	EP1719756A1 Nitrogenous fused heteroaromatic ring derivative
11/08/2006	EP1719543A1 Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
11/08/2006	EP1719527A1 Antitumor agent
11/08/2006	EP1719526A2 Pharmaceutical combinations comprising a P2T receptor antagonist and another anti-thrombotic agent
11/08/2006	EP1719525A1 NUCLEAR TRANSFER PROMOTER FOR Cdc42 PROTEIN AND METHOD OF SCREENING THE SAME
11/08/2006	EP1719524A1 Nuclear transfer promoter for rac protein and method of screening the same
11/08/2006	EP1719519A1 Dietary supplement kit
11/08/2006	EP1719518A1 Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals
11/08/2006	EP1719516A1 A pharmaceutical composition used for treating recurrent spontaneous abortion and method thereof
11/08/2006	EP1719515A2 Glycyrrhizin or derivatives thereof for treating or preventing togavirus infections
11/08/2006	EP1719514A1 Drug for treating pain
11/08/2006	EP1719513A1 Method of preventing, medicating and/or treating hypocalcaemia of domestic mammal
11/08/2006	EP1719512A2 Sarsasapogenin and smilagenin for treating cognitive dysfunctions
11/08/2006	EP1719511A2 N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
11/08/2006	EP1719510A1 Use of creatine or creatine analogs for the tratment of diseases of the nervous system
11/08/2006	EP1719509A1 Use of 2,5-dihydroxybenzenesulphonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis
11/08/2006	EP1719508A1 Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction
11/08/2006	EP1719507A1 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
11/08/2006	EP1719506A1 Gene expression controlling agent
11/08/2006	EP1719505A2 Pharmaceutical formulations for dry powder inhalers in the form of hard pellets
11/08/2006	EP1719504A1 Solid transdermal therapeutic system with UV-absorber
11/08/2006	EP1719503A1 Use of debranched starch in extrusion-spheronization pharmaceutical pellets
11/08/2006	EP1719502A1 Composition for easing human childbirth
11/08/2006	EP1719496A2 Method for producing purified hematinic iron-saccharidic complex and product produced
11/08/2006	EP1719495A2 Method for producing purified hematinic iron-saccharidic complex and product produced
11/08/2006	EP1718788A2 Method for providing antimicrobial composite yarns, composite fabrics and articles made therefrom
11/08/2006	EP1718762A1 Antisense oligonucleotide modulation of stat3 expression
11/08/2006	EP1718755A1 Method for the production of hyperbranched polysaccharide fractions
11/08/2006	EP1718747A2 Stabilized rnas as transfection controls and silencing reagents
11/08/2006	EP1718741A2 Treatment of neurodegenerative diseases by the use of atp7a
11/08/2006	EP1718667A2 Heterocyclic self-immolative linkers and conjugates
11/08/2006	EP1718659A1 Vectors having both isoforms of beta-hexosaminidase and uses of the same
11/08/2006	EP1718653A1 Glucocorticoid receptor modulator compounds and methods- utility
11/08/2006	EP1718651A2 7h-pyrrolopyrimidine derivatives

1 ... 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 ... 7860